Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 16, 2016

Primary Completion Date

February 8, 2018

Study Completion Date

May 5, 2021

Conditions

Chronic Hepatitis B

Interventions

DRUG

TAF

Tablet administered orally

DRUG

TDF

Tablet administered orally

DRUG

Other approved antivirals

Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice

Trial Locations (1)

Auckland City Hospital, Auckland